Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: GlobeNewswire
2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year 2,400 People Living with Fabry Disease on Galafold® Following a Year of Increased Demand Expecting 2024 Galafold Revenue Growth of 11-16% at CER Successful Launches of Pombiliti™ + Opfolda™ Underway in the U.S., U.K., and Germany PRINCETON, N.J., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided its preliminary and unaudited 2023 revenue, corporate updates, and full-year 2024 outlook. In 2023, Amicus met or exceeded its strategic priorities, highlighted by: Sustaining double-digit Galafold revenue growthSecuring FDA, EMA, and MHRA approvals for Pombiliti + OpfoldaInitiating successful global launches of Pombiliti + OpfoldaAdvancing next-generation pipeline programsOn-track to achieving non-GAAP profitability in the fourth quarter of 2023 Preliminary and Un
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Become Profitable? [Yahoo! Finance]Yahoo! Finance
- Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) ReportGlobeNewswire
- Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at JPMorgan Chase & Co. from $21.00 to $19.00. They now have an "overweight" rating on the stock.MarketBeat
FOLD
Earnings
- 2/28/24 - Beat
FOLD
Sec Filings
- 4/24/24 - Form ARS
- 4/24/24 - Form DEF
- 4/24/24 - Form DEFA14A
- FOLD's page on the SEC website